Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT01410188 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open-angle Glaucoma
Ocular Hypertension

Interventions

DRUG: OPA-6566
DRUG: Placebo
DRUG: Latanoprost

Sponsor

Kubota Vision Inc.

Collaborators

[object Object]